Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”
Titel:
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”
Auteur:
Schöffski, Patrick Toulmonde, Maud Estival, Anna Marquina, Gloria Dudzisz-Śledź, Monika Brahmi, Mehdi Steeghs, Neeltje Karavasilis, Vasilios de Haan, Jacco Wozniak, Agnieszka Cousin, Sophie Domènech, Marta Bovée, Judith V.M.G. Charon-Barra, Céline Marreaud, Sandrine Litière, Saskia De Meulemeester, Laura Olungu, Christine Gelderblom, Hans